Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 5,521 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Sickle Cell Disease
Interventions: Placebo, Mometasone; Drug
Lead sponsor: Jeffrey Glassberg; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: New York, New York

Conditions: Heart Failure, Gastrointestinal Bleeding
Interventions: Omega 3 fatty acids, Placebo; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 74
States / cities: Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more

Conditions: Cytomegalovirus Infection
Interventions: MBX400, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Thalassemia
Interventions: Zinc, Placebo; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 6 Years to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Oakland, California • San Francisco, California • Philadelphia, Pennsylvania

Conditions: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 83
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more

Conditions: Bacterial Vaginosis, Herpes Simplex Virus Type II
Interventions: Placebo, Valacyclovir; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: docetaxel, placebo, prednisone, bevacizumab, laboratory biomarker analysis; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Chicago, Illinois

Conditions: Leukemia, Myeloid, Acute
Interventions: Cytarabine, Idasanutlin, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Great Neck, New York • Hawthorne, New York • New York, New York + 3 more

Conditions: HBeAg-negative Chronic Hepatitis B
Interventions: TAF, TDF, TAF Placebo, TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more

Conditions: mCRPC
Interventions: Placebo, Senaparib; Drug
Lead sponsor: Impact Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Binghamton, New York

Conditions: Myelofibrosis, Anemia
Interventions: Placebo, Elritercept; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 35
States / cities: Gilbert, Arizona • Glendale, California • Whittier, California + 27 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 65
States / cities: Mesa, Arizona • Artesia, California • Buena Park, California + 54 more

Conditions: Type 1 Diabetes
Interventions: Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Systemic Lupus Erythematosus
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C; Drug
Lead sponsor: GLWL Research Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Tempe, Arizona • Chula Vista, California • Miami, Florida + 1 more

Conditions: Liver Cirrhosis, Biliary
Interventions: INT-747, Ursodeoxycholic Acid (URSO), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: PTSD
Interventions: NYX-783, Placebo; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 33 more

Conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania
Interventions: Placebo, Memantine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastroesophageal Reflux
Interventions: XP19986 SR3, 20 mg QD, XP19986 SR3, 40 mg QD, XP19986 SR3, 60 mg QD, XP19986 SR3, 30 mg BID, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Irvine, California

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: GS-9674, Placebo to match GS-9674; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 26
States / cities: Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more

Conditions: Healthy
Interventions: Cranberry Beverage, Placebo Beverage; Other
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 35 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

Zinc & Bone Health in Thalassemia: The Think Zinc Study

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Inflammation and Insulin Resistance in Rheumatoid Arthritis

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Memantine in Body Focused Repetitive Behaviors

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Cranberry Consumption Improves γδ T Cell Function